RHJA
IRMD icon

Rice Hall James & Associates’s iRadimed IRMD Stock Holding History

Rice Hall James & Associates’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.49M Sell
36,289
-704
-2% -$70.4K 0.19% 113
2025
Q4 		$3.6M Sell
36,993
-6,600
-15% -$566K 0.2% 113
2025
Q3 		$3.1M Sell
43,593
-20,429
-32% -$1.36M 0.17% 121
2025
Q2 		$3.83M Sell
64,022
-5,472
-8% -$300K 0.21% 105
2025
Q1 		$3.65M Sell
69,494
-384
-0.5% -$21.6K 0.21% 103
2024
Q4 		$3.84M Sell
69,878
-1,721
-2% -$90.6K 0.21% 107
2024
Q3 		$3.6M Sell
71,599
-439
-0.6% -$20.3K 0.19% 118
2024
Q2 		$3.17M Sell
72,038
-4,673
-6% -$199K 0.19% 120
2024
Q1 		$3.37M Sell
76,711
-166
-0.2% -$7.34K 0.19% 112
2023
Q4 		$3.65M Sell
76,877
-629
-0.8% -$26.4K 0.21% 109
2023
Q3 		$3.44M Buy
77,506
+12,960
+20% +$602K 0.22% 107
2023
Q2 		$3.08M Sell
64,546
-7,725
-11% -$348K 0.17% 133
2023
Q1 		$2.84M Sell
72,271
-967
-1% -$35.1K 0.16% 150
2022
Q4 		$2.07M Sell
73,238
-2,968
-4% -$84.9K 0.12% 185
2022
Q3 		$2.29M Buy
76,206
+162
+0.2% +$5.64K 0.13% 169
2022
Q2 		$2.58M Sell
76,044
-5,072
-6% -$182K 0.12% 167
2022
Q1 		$3.64M Sell
81,116
-48,814
-38% -$2.26M 0.14% 139
2021
Q4 		$6M Buy
129,930
+9,531
+8% +$385K 0.21% 92
2021
Q3 		$4.04M Sell
120,399
-91,926
-43% -$3.13M 0.15% 111
2021
Q2 		$6.24M Sell
212,325
-18,000
-8% -$496K 0.22% 82
2021
Q1 		$5.93M Buy
230,325
+1,531
+0.7% +$36.6K 0.19% 93
2020
Q4 		$5.22M Buy
228,794
+7,287
+3% +$168K 0.18% 97
2020
Q3 		$4.74M Buy
221,507
+72,898
+49% +$1.64M 0.19% 103
2020
Q2 		$3.45M Buy
148,609
+79,689
+116% +$1.71M 0.15% 121
2020
Q1 		$1.47M Buy
68,920
+12,109
+21% +$288K 0.08% 166
2019
Q4 		$1.33M Buy
+56,811
New +$1.33M 0.04% 215

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rice Hall James & Associates's IRMD Position: Q1 2026 in Review

Rice Hall James & Associates reduced its iRadimed (IRMD) stake by 1.9% in Q1 2026, selling an estimated $70.4K and leaving 36,289 shares worth $3.49M. The position accounts for 0.19% of the portfolio, ranked #113.

Rice Hall James & Associates first reported a position in IRMD in Q4 2019 and has held it in 26 quarters since. The position peaked at $6.24M in Q2 2021. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Rice Hall James & Associates held 36,289 shares of iRadimed worth $3.49M as of Q1 2026.
  • Rice Hall James & Associates sold 704 iRadimed shares in Q1 2026, an estimated $70.4K.
  • iRadimed made up 0.19% of Rice Hall James & Associates's portfolio in Q1 2026, its #113 holding.
  • Rice Hall James & Associates first reported a position in iRadimed in Q4 2019 and has held it in 26 quarters since.
  • Rice Hall James & Associates's iRadimed position peaked at $6.24M in Q2 2021.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.